Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bullish Derivatives Activity

Open Interest Spike Reflects Growing Market Interest

On 23 April 2026, Zydus Lifesciences (symbol: ZYDUSLIFE) recorded an open interest (OI) of 20,801 contracts in its futures and options segment, marking a substantial increase of 4,125 contracts or 24.74% compared to the previous session’s 16,676 contracts. This sharp rise in OI is indicative of fresh positions being established rather than existing ones being squared off, suggesting renewed conviction among market participants.

The total volume for the day stood at 31,485 contracts, underscoring active trading interest. The futures segment alone accounted for a notional value of approximately ₹79,236 lakhs, while the options segment’s notional value was significantly higher at ₹19,372.77 crores, culminating in a combined derivatives turnover of ₹81,241.05 lakhs. Such elevated volumes and values highlight the stock’s liquidity and attractiveness for derivatives traders.

Price Momentum Supports Bullish Sentiment

Zydus Lifesciences outperformed its Pharmaceuticals & Biotechnology sector by 0.27% on the day, registering a 1.98% gain. The stock has been on a positive trajectory, gaining 2.19% over the last two consecutive sessions. Intraday, it touched a high of ₹962.90, a 3.55% rise from the previous close, and is currently trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling sustained upward momentum.

Despite this price strength, delivery volumes have declined by 37.86% compared to the five-day average, with only 1.45 lakh shares delivered on 22 April. This divergence suggests that while short-term speculative interest is rising, longer-term investor participation remains subdued, possibly reflecting cautious optimism amid broader market uncertainties.

Market Positioning and Directional Bets

The surge in open interest combined with rising prices typically points to fresh long positions being initiated, reflecting bullish sentiment among traders. The increase in futures OI and the substantial options notional value imply that participants are actively deploying strategies to capitalise on anticipated upward price movements.

Options data, with a notional value exceeding ₹19,372 crores, suggests significant activity in call options, which are often used to express bullish directional bets or hedge existing positions. The elevated open interest in options could also indicate complex strategies such as spreads or straddles being employed to manage risk while positioning for volatility.

Given the stock’s mid-cap status with a market capitalisation of ₹95,340.67 crores and a Mojo Score of 48.0, the recent downgrade from Hold to Sell on 1 December 2025 by MarketsMOJO adds an intriguing dimension. The downgrade reflects concerns over valuation or near-term fundamentals, yet the current derivatives activity suggests that traders are either anticipating a reversal or exploiting short-term price swings.

Technical and Fundamental Context

Trading above all major moving averages, Zydus Lifesciences is demonstrating technical strength that often attracts momentum traders and short-term investors. The stock’s ability to outperform the sector and the broader Sensex, which declined by 0.87% on the same day, further emphasises its relative resilience.

However, the falling delivery volumes caution against over-exuberance, signalling that institutional or long-term investors may be holding back. This mixed participation profile could lead to increased volatility in the near term as speculative traders dominate price action.

From a fundamental perspective, the mid-cap pharmaceutical company’s downgrade to a Sell rating by MarketsMOJO, with a Mojo Grade of 48.0, reflects concerns that may include pricing pressures, regulatory challenges, or competitive dynamics within the sector. Investors should weigh these factors carefully against the current bullish technical signals and derivatives market activity.

Implications for Investors and Traders

The pronounced increase in open interest and volume in Zydus Lifesciences derivatives suggests that market participants are positioning for a directional move, likely to the upside given the price action and technical indicators. Traders may consider this an opportunity to capitalise on momentum, employing futures and options strategies to leverage potential gains.

Conversely, the fundamental downgrade and subdued delivery volumes advise caution, especially for long-term investors. The divergence between derivatives activity and underlying investor participation could result in sharp price corrections if broader market sentiment shifts or if company-specific risks materialise.

Overall, the current market positioning in Zydus Lifesciences reflects a complex interplay of optimism and caution, with derivatives markets signalling increased speculative interest amid a backdrop of fundamental uncertainty.

Conclusion: Navigating the Derivatives-Driven Momentum

Zydus Lifesciences Ltd’s recent surge in open interest and trading volumes in the derivatives market underscores a notable shift in market sentiment. The stock’s outperformance relative to its sector and the broader market, coupled with strong technical positioning, has attracted speculative interest and directional bets, primarily bullish in nature.

However, the fundamental downgrade and declining delivery volumes highlight underlying risks and a cautious stance among long-term investors. This dichotomy suggests that while short-term momentum may persist, investors should remain vigilant and consider the broader context before committing capital.

For traders, the current environment offers opportunities to exploit volatility and directional moves using futures and options. For investors, a balanced approach that incorporates both technical signals and fundamental assessments will be essential to navigate the evolving landscape of Zydus Lifesciences Ltd.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →